All In Biotech

Free tool

FAERS Monitor: Retrovir

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019951 or its brand name (Retrovir, Zidovudine). Reports on generic versions are filed under their own applications.

Reports

13,354

Serious

12,637

95% of reports

Hospitalization

3,356

Death reported

1,659

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • foetal exposure during pregnancy2,183
  • drug exposure during pregnancy1,074
  • anaemia937
  • virologic failure816
  • drug resistance732
  • premature baby731
  • exposure during pregnancy663
  • pathogen resistance599
  • viral mutation identified568
  • maternal exposure during pregnancy523
  • pyrexia471
  • lipodystrophy acquired436
  • pain427
  • treatment failure423
  • death418

Reports by year received

View as table
YearReports
2004544
2005542
2006791
2007608
2008579
2009630
2010597
2011465
2012423
2013408
2014457
2015697
20161,264
2017987
2018834
2019722
2020908
2021541
2022460
2023398
2024193
2025148
2026143

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,805 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lipodystrophy acquiredSignal436406.7366.6139,949
viral mutation identifiedSignal568286.9262.8136,694
virologic failureSignal816281.5261.8193,327
pathogen resistanceSignal599110.7102.160,771
drug exposure during pregnancySignal1,07451.348.451,366
drug resistanceSignal73246.243.031,421
foetal exposure during pregnancySignal2,18343.441.888,380
premature babySignal73139.236.526,539
exposure during pregnancySignal66317.015.89,872
maternal exposure during pregnancySignal5239.38.53,855
treatment failureSignal4238.17.42,613
anaemiaSignal9377.87.35,545
pyrexiaSignal4712.12.0291
pain4271.11.04
death4180.80.731

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.